

Clinical Trial Protocol

Iranian Registry of Clinical Trials

28 May 2026

Library study of kidney stone dissolving medicaments in Persian medicine and evaluation of a related multi-ingredient formulation in dissolving calcium kidneystones; a double-blind randomized clinical trial

Protocol summary

Study aim

Preparation of new herbal formulations for kidney stones

Design

Sixty patients will be divided into two groups of 30, one group will receive medication for 6 weeks and the control group will receive a placebo. At the beginning and end of the study, the results of the analysis of urine and blood samples and imaging will be examined.

Settings and conduct

The study is done in Motahhari and Imam Reza clinics affiliated to Shiraz University of Medical Sciences. After examining the patient and confirming the conditions for admission to the study and obtaining informed consent, the doctor will provide the patient with a medicine or placebo.

Participants/Inclusion and exclusion criteria

Age 18 years and older
5 mm calcium kidney stones in the lower lobe
Willingness to participate in the study
No pregnancy and lactation
Lack of acute and chronic renal failure

Intervention groups

30 patients in intervention group consume 2 capsules of freeze dried water extract of 6 plants daily. 30 patients in control group consumes 2 capsules of wheat flour as placebo daily.

Main outcome variables

kidney function test, liver function test, Ca and P serum levels, urine analysis, 24 h urine volume and stone diameter

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20191212045709N1**

Registration date: **2020-09-29, 1399/07/08**

Registration timing: **registered_while_recruiting**

Last update: **2020-09-29, 1399/07/08**

Update count: **0**

Registration date

2020-09-29, 1399/07/08

Registrant information

Name

Ramin Ansari

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 71 3242 4255

Email address

ansariramin94@gmail.com

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2020-01-15, 1398/10/25

Expected recruitment end date

2020-11-21, 1399/09/01

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Library study of kidney stone dissolving medicaments in Persian medicine and evaluation of a related multi-ingredient formulation in dissolving calcium kidneystones; a double-blind randomized clinical trial

Public title

Library study of kidney stone dissolving medicaments in Persian medicine and evaluation of a related multi-ingredient formulation in dissolving calcium kidneystones; a double-blind randomized clinical trial

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria:

Age 18 years and older Calcium kidney stones with a size of 5 mm or more based on imaging results Lack of confirmed history of acute renal failure Lack of confirmed history of chronic kidney disease having no present urinary tract infection no concurrent use of medications including:®Sankol, ®Rowatinex and Cystone® no pregnancy or breast feeding

Exclusion criteria:

Age 18 years and older Calcium kidney stones with a size of 5 mm or more based on imaging results Lack of confirmed history of acute renal failure Lack of confirmed history of chronic kidney disease having no present urinary tract infection no concurrent use of medications including:®Sankol, ®Rowatinex and Cystone® no pregnancy or breast feeding

Age

From **18 years** old to **65 years** old

Gender

Both

Phase

3

Groups that have been masked

- Participant
- Care provider
- Investigator

Sample size

Target sample size: **60**

Randomization (investigator's opinion)

Randomized

Randomization description

A total of 60 patients were randomly divided in to two groups of 30 each in a randomized double-blind placebo-controlled design using permuted block randomization method. The sample size and randomization were done by a computer- generated statistical program. Minimum sample size for each group was 13 patients. All patients received either 2 capsules of drug or identical-looking placebos at a dose of 2 capsules once daily for a period of 6 weeks.

Blinding (investigator's opinion)

Double blinded

Blinding description

The study will be a double blind trial and only the evaluator knows the results and the code of the drug or placebo group.The capsules of the drug group and the placebo are quite similar in appearance.The drug and placebo groups will be separated by receiving a code.

Placebo

Used

Assignment

Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Ethics committee of Shiraz University of Medical Sciences

Street address

anvari str- zand blvd- shiraz

City

shiraz

Province

Fars

Postal code

7139745197

Approval date

2019-11-06, 1398/08/15

Ethics committee reference number

IR.SUMS.REC.1398.924

Health conditions studied

1

Description of health condition studied

renal stone

ICD-10 code

ICD-10 code description

Primary outcomes

1

Description

liver function test- renal function test-Ca and P serum level, urine analysis, 24 hour urine volume and stone diameter

Timepoint

At the beginning of the study and one month after the end of the course of medication

Method of measurement

KUB- URINE ANALYSIS-BLOOD ANALYSIS

Secondary outcomes

empty

Intervention groups

1

Description

The intervention group consumes 2 capsules (one in the morning and one at night) of freeze dried water extract of 6 plants including: Tribulus terrestris-Foeniculum vulgare-Pimpinella anisum- Cucumis sativus-Cucurbita pepo-Apium graveolens. the control group consumes 2

capsules of wheat flour as placebo daily. Blood sample and 24 hours urine of patients will be analyzed at the beginning and end of the study and the imaging will be done for analyzing the size and number of stones.

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

SHAHID MOTAHARI CLINIC

Full name of responsible person

MOHAMMAD MEHDI ZARSHENAS

Street address

NAMAZI SQUARE- SHIRAZ

City

SHIRAZ

Province

Fars

Postal code

7193613311

Phone

+98 71 3647 4332

Fax

+98 71 3647 4361

Email

NEMAZEE-INF@SUMS.AC.IR

Web page address

<https://namazi.sums.ac.ir/page-Namazi/fa/65/form/pld5524>

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Shiraz University of Medical Sciences

Full name of responsible person

دانشگاه علوم پزشکی شیراز

Street address

ZAND BLVD. SHIRAZ

City

SHIRAZ

Province

Fars

Postal code

7134814336

Phone

+98 71 3230 5410

Fax

+98 71 3230 5411

Email

INFO@SUMS.AC.IR

Web page address

<https://sums.ac.ir/page-Main/fa/0/form/pld656>

Grant name**Grant code / Reference number****Is the source of funding the same sponsor****organization/entity?**

Yes

Title of funding source

Shiraz University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin**Type of organization providing the funding**

Academic

Person responsible for general inquiries

Contact**Name of organization / entity**

Shiraz University of Medical Sciences

Full name of responsible person

MM ZARSHENAS

Position

ASSISTANT PROFESSOR

Latest degree

Ph.D.

Other areas of specialty/work

Medical Pharmacy

Street address

SHIRAZ FACULTY OF PHARMACY

City

SHIRAZ

Province

Fars

Postal code

713451583

Phone

+98 917 711 3491

Fax

+98 71 3242 4126

Email

ZARM@SUMS.AC.IR

Web page address

<https://pharmacy.sums.ac.ir/page-pharmacy/fa/79/form/pld10611>

Person responsible for scientific inquiries

Contact**Name of organization / entity**

Shiraz University of Medical Sciences

Full name of responsible person

MM ZARSHENAS

Position

ASSISTANT PROFESSOR

Latest degree

Ph.D.

Other areas of specialty/work

Medical Pharmacy

Street address

FACULTY OF PHARMACY SHIRAZ

City

SHIRAZ

Province

Fars

Postal code

71۴۶۸۶۴۶۸۵

Phone

+98 71 3242 6122

Fax

+98 71 3242 6122

Email

ZARM@SUMS.AC.IR

Web page address

<https://pharmacy.sums.ac.ir/page-pharmacy/fa/79/form/pld9914>

Person responsible for updating data

Contact

Name of organization / entity

Shiraz University of Medical Sciences

Full name of responsible person

MM ZARSHENAS

Position

ASSISTANT PROFESSOR

Latest degree

Ph.D.

Other areas of specialty/work

Medical Pharmacy

Street address

FACULTY OF PHARMACY

City

SHIRAZ

Province

Fars

Postal code

713451583

Phone

+98 71 3242 4127

Fax

+98 71 3242 4127

Email

ZARM@SUMS.AC.IR

Web page address

<https://pharmacy.sums.ac.ir/page-pharmacy/fa/79/form/pld10611>

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Yes - There is a plan to make this available

Study Protocol

Undecided - It is not yet known if there will be a plan to make this available

Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to make this available

Informed Consent Form

Undecided - It is not yet known if there will be a plan to make this available

Clinical Study Report

Undecided - It is not yet known if there will be a plan to make this available

Analytic Code

Undecided - It is not yet known if there will be a plan to make this available

Data Dictionary

Undecided - It is not yet known if there will be a plan to make this available

Title and more details about the data/document

JUST THE RESULTS WILL BE PUBLISHED

When the data will become available and for how long

AT THE END OF THE STUDY

To whom data/document is available

UNIVERSITIES

Under which criteria data/document could be used

SCIENTIFIC RESEARCH

From where data/document is obtainable

ZARM@SUMS.AC.IR

What processes are involved for a request to access data/document

CONTACT ZARM@SUMS.AC.IR

Comments